Daniel Schmitt
Chief Executive Officer at Actuate Therapeutics, Inc.
Net worth: 10 $ as of 2024-06-29
Profile
Daniel M.
Schmitt is currently the President, Chief Executive Officer & Director at Actuate Therapeutics, Inc. He previously worked as the Director-Academic Partnerships at First Genetic Trust, Inc. and as the SVP-Licensing & Commercial Development at Immtech Pharmaceuticals, Inc. He holds an undergraduate degree and an MBA from West Virginia University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
Actuate Therapeutics, Inc.
 Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. 4.61% | 2024-04-30 | 1,003,421 ( 4.61% ) | 10 $ | 2024-06-29 |
Daniel Schmitt active positions
| Companies | Position | Start |
|---|---|---|
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Chief Executive Officer | 2015-02-28 |
| Chicago Innovation Mentors | Corporate Officer/Principal | - |
Former positions of Daniel Schmitt
| Companies | Position | End |
|---|---|---|
Genus Oncology LLC
 Genus Oncology LLC BiotechnologyHealth Technology Genus Oncology LLC operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers. The company was founded in 2007 and is headquartered in Chicago, IL. | Chief Operating Officer | 2013-12-31 |
Immtech Pharmaceuticals, Inc.
 Immtech Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immtech Pharmaceuticals, Inc. develops and distributes pharmaceuticals. The company's efforts reflect extensive work in clinical research, new product development and marketing. The company focuses on developing a new treatment for the Hepatitis C virus. Immtech Pharmaceuticals was founded on October 15, 1984 and is headquartered in New York, NY. | Corporate Officer/Principal | 2008-12-31 |
First Genetic Trust, Inc.
 First Genetic Trust, Inc. Medical/Nursing ServicesHealth Services First Genetic Trust, Inc. provides genetic data handling and bioinformatics services to pharmaceutical companies, medical researchers and health care providers. The company was founded in 2000 by Arthur L. Holden and is headquartered in Deerfield, IL. | Corporate Officer/Principal | 2003-12-31 |
Training of Daniel Schmitt
| West Virginia University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immtech Pharmaceuticals, Inc. develops and distributes pharmaceuticals. The company's efforts reflect extensive work in clinical research, new product development and marketing. The company focuses on developing a new treatment for the Hepatitis C virus. Immtech Pharmaceuticals was founded on October 15, 1984 and is headquartered in New York, NY. | Health Technology |
First Genetic Trust, Inc.
First Genetic Trust, Inc. Medical/Nursing ServicesHealth Services First Genetic Trust, Inc. provides genetic data handling and bioinformatics services to pharmaceutical companies, medical researchers and health care providers. The company was founded in 2000 by Arthur L. Holden and is headquartered in Deerfield, IL. | Health Services |
Genus Oncology LLC
Genus Oncology LLC BiotechnologyHealth Technology Genus Oncology LLC operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing first-in-class agents against the MUC1-C oncoprotein for the treatment of patients with refractory cancers. The company was founded in 2007 and is headquartered in Chicago, IL. | Health Technology |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Health Technology |
| Chicago Innovation Mentors |
- Stock Market
- Insiders
- Daniel Schmitt
